Tanezumab for difficult-to-treat OA makes good in phase III trial
27 Apr 2020
byJairia Dela Cruz
Treatment with subcutaneous tanezumab 5 mg yields significant improvements in pain, physical function and PGA-OA in patients with moderate-to-severe osteoarthritis (OA) who have not responded to or could not tolerate standard-of-care analgesics, according to the results of a phase III trial.
